Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?-Reference-Cited by-同舟云学术

Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?

Published:2022-06-28 Issue:5 Volume:149 Page:1849-1862
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Möhring Christian,Timotheou Aliki,Mańczak Adrianna,Sadeghlar Farsaneh,Zhou Taotao,Mahn Robert,Bartels Alexandra,Monin Malte,Toma Marieta,Feldmann Georg,Brossart Peter,Köksal Mümtaz,Sarria Gustavo R.,Giordano Frank A.,Lingohr Philipp,Jafari Azin,Kalff Jörg C.,Strassburg Christian P.,Gonzalez-Carmona Maria A.^ORCID

Funder

Deutsche Krebshilfe

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04109-8.pdf

Reference36 articles.

1. Al-Batran S, Hartmann J, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E (2008) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19(11):1882–1887. https://doi.org/10.1093/annonc/mdn403

2. Al-Batran S et al (2017) Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 3(9):1237–1244. https://doi.org/10.1001/jamaoncol.2017.0515

3. Al-Batran S et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet (london, England) 393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1

4. Al-Batran S, Moorahrend E, Maintz C, Goetze T, Hempel D, Thuss-Patience P, Gaillard V, Hegewisch-Becker S (2020) Clinical practice observation of trastuzumab in patients with human epidermal growth receptor 2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction. Oncologist 25(8):e1181–e1187. https://doi.org/10.1634/theoncologist.2020-0109

5. Al-Batran S, Pauligk C, Homann N, Hartmann J, Moehler M, Probst S, Rethwisch V, Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, Bokemeyer C, Mahlberg R, Hofheinz R, Luley K, Kullmann F, Jäger E (2013) The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer (oxford, England: 1990). https://doi.org/10.1016/j.ejca.2012.09.025

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eficacia y tolerancia del tratamiento perioperatorio con esquema FLOT en pacientes con adenocarcinoma gástrico y la de unión gastroesofágica, tratados en el Hospital Italiano de buenos aires;Oncología Clínica;2023-12-15

2. Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real‐world cohort;International Journal of Cancer;2023-05-05

3. The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion;Frontiers in Medicine;2022-12-15